USAha Produksi Le-mush (Lempeng Mushroom) Dari Jamur Tiram Sebagai Makanan Alternatif MSG (Murah, Sehat, Dan Gizi Tinggi)

Banjar Plates is a very well known Banjarmasin communities in Southern Borneo region but not yet have a sale value. Based on facts, oyster mushroom contains some nutritions for our health. But, in culinary industry oyster mushroom is really few. Actually, oyster mushroom is just made for soup or additional ingridients for beverage and this thing make oyster mushroom has less value for society. In this part, we made a new kind of food from oyster mushroom that is delicious, interesting, and innovative plate and also has more USAge for society. Mushroom plate has 2 main flavours, chilly and sweet. Each of flavour, we also made some variant flavours, original, cheese, sausage, beef shredded, chicken shredded, cheese + sausage, and also has a good price Rp6.000,00 for original, Rp7.000,00 for cheese, sausage, beef shredded, Rp8.000,00 for chicken shredded and cheese + sausage. Our marketing method is selling alongside of the road or in a store and the customer that want to buy just choose the variant and wait for 5 minutes and Plate is ready to serve in place or their could take home.After we sold it for 4 months, we realized that the customer really appreciated our product. This thing also supported by the chart that always grew up for each month. And finally, we really sure that this product will be famous in the future

Organization and Running of the First Comprehensive Hereditary Cancer Clinic in India

Hereditary cancers are thought to account for around 5% of cancers, particularly breast/ovarian and colorectal cancers. In India there is a paucity of data on hereditary cancers and the mutations in some of the common genes linked to hereditary cancers, such as BRCA1, BRCA2, hMSH2 and hMLH1. The country's first comprehensive hereditary cancer clinic was established in February 2002. The article describes the organization and running of the Clinic. It also discusses some of the social issues relevant to the given population in running the Hereditary Cancer Clinic

Identification of Nephelium lappaceum leaves phenolic and flavonoid component with radical scavenging, antidiabetic and antibacterial potential

360-365Nephelium lappaceum Linn. (Rambutan) is traditionally claimed, as a source of natural antioxidants and for its use in the treatment of diabetes and bacterial infections. The present study investigates the in vitro effect of ethanolic Rambutan leaves extract (NL) for its antioxidant effect, α-glucosidase, α-amylase enzyme inhibition, and antibacterial potentials. The total phenolic, total flavonoid content of NL was quantified and were expressed in terms of gallic acid (19.6±0.04 mg GAE/g) and rutin equivalents (16.7±0.01 mg RUE/g) respectively. The antioxidant assay revealed that NL exhibited significant inhibition of DPPH (IC50±SEM: 1.52±0.03 μg/mL) and ABTS (IC50±SEM: 1.295±0.05 μg/mL) radicals. NL also inhibited both α-amylase (IC50±SEM: 2.624±0.07 μg/mL), α-glucosidase (IC50±SEM: 2.416±0.06 μg/mL) enzyme activities, supported by its antioxidant potential and its phenolic and flavonoid content. The antibacterial activity was screened against seven human pathogenic ATCC strains for which the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were recorded. The selected MIC dose was tested, confirmed by Kirby-Bauer agar well diffusion method. NL exhibited MIC and MBC of 62.5 μg/mL and 125 μg/mL against B.subtilis and E.coli respectively. The results support the scientific claim of NL for its antioxidant, antidiabetic and antibacterial potential

Identification of Nephelium lappaceum leaves phenolic and flavonoid component with radical scavenging, antidiabetic and antibacterial potential

360-365Nephelium lappaceum Linn. (Rambutan) is traditionally claimed, as a source of natural antioxidants and for its use in the treatment of diabetes and bacterial infections. The present study investigates the in vitro effect of ethanolic Rambutan leaves extract (NL) for its antioxidant effect, α-glucosidase, α-amylase enzyme inhibition, and antibacterial potentials. The total phenolic, total flavonoid content of NL was quantified and were expressed in terms of gallic acid (19.6±0.04 mg GAE/g) and rutin equivalents (16.7±0.01 mg RUE/g) respectively. The antioxidant assay revealed that NL exhibited significant inhibition of DPPH (IC50±SEM: 1.52±0.03 μg/mL) and ABTS (IC50±SEM: 1.295±0.05 μg/mL) radicals. NL also inhibited both α-amylase (IC50±SEM: 2.624±0.07 μg/mL), α-glucosidase (IC50±SEM: 2.416±0.06 μg/mL) enzyme activities, supported by its antioxidant potential and its phenolic and flavonoid content. The antibacterial activity was screened against seven human pathogenic ATCC strains for which the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were recorded. The selected MIC dose was tested, confirmed by Kirby-Bauer agar well diffusion method. NL exhibited MIC and MBC of 62.5 μg/mL and 125 μg/mL against B.subtilis and E.coli respectively. The results support the scientific claim of NL for its antioxidant, antidiabetic and antibacterial potential

Growth and Morbidity of Gambian Infants are Influenced by Maternal Milk Oligosaccharides and Infant Gut Microbiota.

Human milk oligosaccharides (HMOs) play an important role in the health of an infant as substrate for beneficial gut bacteria. Little is known about the effects of HMO composition and its changes on the morbidity and growth outcomes of infants living in areas with high infection rates. Mother's HMO composition and infant gut microbiota from 33 Gambian mother/infant pairs at 4, 16, and 20 weeks postpartum were analyzed for relationships between HMOs, microbiota, and infant morbidity and growth. The data indicate that lacto-N-fucopentaose I was associated with decreased infant morbidity, and 3'-sialyllactose was found to be a good indicator of infant weight-for-age. Because HMOs, gut microbiota, and infant health are interrelated, the relationship between infant health and their microbiome were analyzed. While bifidobacteria were the dominant genus in the infant gut overall, Dialister and Prevotella were negatively correlated with morbidity, and Bacteroides was increased in infants with abnormal calprotectin. Mothers nursing in the wet season (July to October) produced significantly less oligosaccharides compared to those nursing in the dry season (November to June). These results suggest that specific types and structures of HMOs are sensitive to environmental conditions, protective of morbidity, predictive of growth, and correlated with specific microbiota

Development of strength models for prediction of unconfined compressive strength of cement/byproduct material improved soils

© 2017 ASTM International. All rights reserved. This paper presents the possible inclusion of pulverized fuel ash (PFA) and ground granulated blast slag (GGBS) in cement deep soil mixing for enhancement of unconfined compressive strength (UCS) of weak soil materials for construction purposes. The main focus of this paper was to investigate the UCS of cement-, cement/PFA-and cement/PFA/GGBS-improved soils, and development of mathematical and graphical models for prediction of UCS for use in design and construction. Samples of cement, blends of cement and PFA, and cement/PFA/GGBS were prepared using 5 %, 10 %, 15 %, and 20 % by weight of dry soil and tested for UCS after 7, 14, 28, and 56 days. A multiple regression analysis was conducted using the SPSS computer program. The results showed that soil materials with lower plasticity show higher strength development compared to those of higher plasticity for cement improvement. The study has also revealed that the inclusion of PFA and GGBS can cause a reduction in the amount of cement in deep soil mixing, which can result to reduced cost and emission of carbon dioxide (CO2) during construction. The developed mathematical and graphical models could give reliable predictions of UCS for weak soil materials with initial UCS less than or equal to 25 kPa and for water to binder ratio of unity based on the observed agreement between experimental and predicted data. The developed multiple regression models have also been validated using different mixtures of 6 %, 8 %, 12 %, and 16 % of binders

Internal states as a source of subject-dependent movement variability and their representation by large-scale networks

AbstractA human’s ability to adapt and learn relies on reflecting on past performance. Such reflections form latent factors called internal states that induce variability of movement and behavior to improve performance. Internal states are critical for survival, yet their temporal dynamics and neural substrates are less understood. Here, we link internal states with motor performance and neural activity using state-space models and local field potentials captured from depth electrodes in over 100 brain regions. Ten human subjects performed a goal-directed center-out reaching task with perturbations applied to random trials, causing subjects to fail goals and reflect on their performance. Using computational methods, we identified two internal states, indicating that subjects kept track of past errors and perturbations, that predicted variability in reaction times and speed errors. These states granted access to latent information indicative of how subjects strategize learning from trial history, impacting their overall performance. We further found that large-scale brain networks differentially encoded these internal states. The dorsal attention network encoded past errors in frequencies above 100 Hz, suggesting a role in modulating attention based on tracking recent performance in working memory. The default network encoded past perturbations in frequencies below 15 Hz, suggesting a role in achieving robust performance in an uncertain environment. Moreover, these networks more strongly encoded internal states and were more functionally connected in higher performing subjects, whose learning strategy was to respond by countering with behavior that opposed accumulating error. Taken together, our findings suggest large-scale brain networks as a neural basis of strategy. These networks regulate movement variability, through internal states, to improve motor performance.Key pointsMovement variability is a purposeful process conjured up by the brain to enable adaptation and learning, both of which are necessary for survival.The culmination of recent experiences—collectively referred to as internal states—have been implicated in variability during motor and behavioral tasks.To investigate the utility and neural basis of internal states during motor control, we estimated two latent internal states using state-space representation that modeled motor behavior during a goal-directed center-out reaching task in humans with simultaneous whole-brain recordings from intracranial depth electrodes.We show that including these states—based on error and environment uncertainty—improves the predictability of subject-specific variable motor behavior and reveals latent information related to task performance and learning strategies where top performers counter error scaled by trial history while bottom performers maintain error tendencies.We further show that these states are encoded by the large-scale brain networks known as the dorsal attention network and default network in frequencies above 100 Hz and below 15 Hz but found neural differences between subjects where network activity closely modulates with states and exhibits stronger functional connectivity for top performers.Our findings suggest the involvement in large-scale brain networks as a neural basis of motor strategy that orchestrates movement variability to improve motor performance.</jats:list-item

Chronic kidney disease in public renal practices in Queensland, Australia, 2011–2018

Aim: To describe adults with (non-dialysis) chronic kidney disease (CKD) in nine public renal practice sites in the Australian state of Queensland. Methods: 7,060 persons were recruited to a CKD Registry in May 2011 and until start of kidney replacement therapy (KRT), death without KRT or June 2018, for a median period of 3.4 years. Results: The cohort comprised 7,060 persons, 52% males, with a median age of 68 yr; 85% had CKD stages 3A to 5, 45.4% were diabetic, 24.6% had diabetic nephropathy, and 51.7% were obese. Younger persons mostly had glomerulonephritis or genetic renal disease, while older persons mostly had diabetic nephropathy, renovascular disease and multiple diagnoses. Proportions of specific renal diagnoses varied >2-fold across sites. Over the first year, eGFR fell in 24% but was stable or improved in 76%. Over follow up, 10% started KRT, at a median age of 62 yr, most with CKD stages 4 and 5 at consent, while 18.8% died without KRT, at a median age of 80 yr. Indigenous people were younger at consent and more often had diabetes and diabetic kidney disease and had higher incidence rates of KRT. Conclusion: The spectrum of characteristics in CKD patients in renal practices is much broader than represented by the minority who ultimately start KRT. Variation in CKD by causes, age, site and Indigenous status, the prevalence of obesity, relative stability of kidney function in many persons over the short term, and differences between those who KRT and die without KRT are all important to explore

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma

Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPGs), are the most lethal of childhood cancers. Palliative radiotherapy is the only established treatment, with median patient survival of 9-11 months. ONC201 is a DRD2 antagonist and ClpP agonist that has shown preclinical and emerging clinical efficacy in DMG. However, further work is needed to identify the mechanisms of response of DIPGs to ONC201 treatment and to determine whether recurring genomic features influence response. Using a systems-biological approach, we showed that ONC201 elicits potent agonism of the mitochondrial protease ClpP to drive proteolysis of electron transport chain and tricarboxylic acid cycle proteins. DIPGs harboring PIK3CA-mutations showed increased sensitivity to ONC201, while those harboring TP53-mutations were more resistant. Metabolic adaptation and reduced sensitivity to ONC201 was promoted by redox-activated PI3K/Akt signaling, which could be counteracted using the brain penetrant PI3K/Akt inhibitor, paxalisib. Together, these discoveries coupled with the powerful anti-DIPG/DMG pharmacokinetic and pharmacodynamic properties of ONC201 and paxalisib have provided the rationale for the ongoing DIPG/DMG phase II combination clinical trial NCT05009992